ストックスクリーナーアプリを入手
129.72
1.36%
1.74
プレマーケット:
130.84
1.12
+0.86%
前日終値:
$127.98
開ける：
$128.975
24時間の取引高:
1.16M
Relative Volume:
0.64
時価総額：
$26.29B
収益：
$5.36B
当期純損益:
$1.43B
株価収益率:
18.34
EPS:
7.0718
ネットキャッシュフロー:
$1.42B
1週間 パフォーマンス:
+5.06%
1か月 パフォーマンス:
+10.24%
6か月 パフォーマンス:
+29.75%
1年 パフォーマンス:
+53.04%
1日の値動き範囲:
$127.50
$130.80
1週間の範囲:
$124.59
$130.80
52週間の値動き範囲:
$81.09
$132.60
Incyte Corp Stock (INCY) Company Profile
Compare INCY vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
129.72 | 25.79B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
552.85 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
833.56 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,019.49 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
158.83 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.38 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | ダウングレード | Jefferies | Buy → Hold |
| 2026-02-05 | 開始されました | H.C. Wainwright | Buy |
| 2026-01-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-11-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-10-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 開始されました | Barclays | Overweight |
| 2025-06-16 | アップグレード | Stifel | Hold → Buy |
| 2025-03-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-18 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 開始されました | UBS | Neutral |
| 2024-10-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-01 | 開始されました | Wolfe Research | Outperform |
| 2024-09-18 | ダウングレード | Truist | Buy → Hold |
| 2024-07-02 | ダウングレード | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 開始されました | Deutsche Bank | Hold |
| 2024-04-23 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 開始されました | Jefferies | Buy |
| 2024-02-14 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-11-21 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-25 | 開始されました | Citigroup | Buy |
| 2023-05-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-04-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 開始されました | Piper Sandler | Overweight |
| 2022-08-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-08-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-07-28 | 開始されました | Wells Fargo | Equal Weight |
| 2022-02-09 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-07-20 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-02-10 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 開始されました | Truist | Buy |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-06-16 | 開始されました | The Benchmark Company | Hold |
| 2020-05-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 再開されました | William Blair | Outperform |
| 2020-03-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 再開されました | BofA/Merrill | Neutral |
| 2020-01-03 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2020-01-03 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-10-03 | 開始されました | Mizuho | Buy |
| 2019-09-12 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-09-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 開始されました | Credit Suisse | Neutral |
| 2019-05-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 開始されました | Stifel | Hold |
| 2019-04-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | アップグレード | William Blair | Mkt Perform → Outperform |
すべてを表示
Incyte Corp (INCY) 最新ニュース
Incyte president Pablo Cagnoni sells $1.36m of INCY shares By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years - Benzinga
Insider Selling: Incyte (NASDAQ:INCY) Insider Sells $1,356,173.56 in Stock - MarketBeat
Incyte Corp's R&D Head Pablo J. Cagnoni Sells 10,801 Shares via 10b5-1 Trading Plan - Kalkine Media
Incyte (INCY) R&D head sells 10,801 shares, holds 183,200 in awards - Stock Titan
INCY Initiates Coverage On Canaccord Genuity -- Rating Set to Bu - GuruFocus
Incyte (INCY) Quarter in Focus: The EPS Result Is Above Expectation for the Current Session; Stock Move: The Market Price Advances 4.05% on the DayRevenue Guidance Update - vinanet.vn
INCY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $150 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on cancer trial data - Investing.com
Incyte (NASDAQ:INCY) Receives Buy Rating from HC Wainwright - MarketBeat
Incyte (NASDAQ:INCY) Earns Buy Rating from Analysts at Canaccord Genuity Group - MarketBeat
H.C. Wainwright reiterates Incyte stock rating on cancer trial data By Investing.com - Investing.com UK
Canaccord Genuity Initiates Incyte at Buy With $152 Price Target - marketscreener.com
DCF Advisers LLC Takes Position in Incyte Corporation $INCY - MarketBeat
BlackRock Inc. Takes $2.04 Billion Position in Incyte Corporation $INCY - MarketBeat
Incyte Corporation: Target Price Consensus and Analysts Recommendations | ICY | US45337C1027 - marketscreener.com
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
US FDA approves Regeneron's rare bone disorder drug - marketscreener.com
INCY Looks 19.9% Overvalued on GF Value™ as Insider Selling Pers - GuruFocus
Incyte (INCY) Financial Update: Profit Per Share Surpasses Its Benchmark in the Latest Reading - Vinanet
State of Wyoming's Incyte Corp(INCY) Holding History - GuruFocus
Incyte Stock: Is Wall Street Bullish or Bearish? - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
INCY Maintained by Piper Sandler -- Price Target Raised to $130 - GuruFocus
Global Vitiligo Foundation Applauds Incyte’s "Moments of Clarity" Campaign for Elevating Patient Voices and Advancing Vitiligo Awareness - Yahoo Finance
Incyte stock holds at the $120 mark as strong quarterly earnings support valuation - AD HOC NEWS
Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup - ChartMill
State of Wyoming Acquires New Holdings in Incyte Corporation $INCY - MarketBeat
LTS:0J9P EV-to-OCF: 10.03 — 48% Below Median - GuruFocus
55,370 Shares in Incyte Corporation $INCY Bought by Summit Global Investments - MarketBeat
Baird Chautauqua Global Growth Fund's Incyte Corp(INCY) Holding History - GuruFocus
Incyte Corp's Pablo J. Cagnoni Sells 10,803 Shares Under Rule 10b5-1 Plan in August 2026 - Kalkine Media
Incyte Corp (INCY) R&D chief sells 10,803 shares under Rule 10b5-1 plan - Stock Titan
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics? - Yahoo Finance
Incyte stock gains support as Q2 2026 sales surge and guidance rises - AD HOC NEWS
Bernstein Adjusts Price Target on Incyte to $104 From $99, Keeps Market Perform Rating - marketscreener.com
Incyte Sales Growth Drives Share Price Gains - FXEmpire
Insight Wealth Strategies LLC Acquires New Position in Incyte Corporation $INCY - MarketBeat
Q4 2025 Incyte Corp Earnings Call Transcript - GuruFocus
Incyte Corp (HAM:ICY) Stock Price, Trades & News - GuruFocus
Incyte Corporation (NASDAQ:INCY): What Could Drive Shares Next? - Kalkine Media
Incyte (INCY) Short Interest & Short Float | Updated Aug 2026 $INCY - MarketBeat
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Bank of America Corp DE Sells 87,913 Shares of Incyte Corporation $INCY - MarketBeat
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Finviz
Incyte Corp (INCY) R&D head sells 10,640 shares in plan trade - Stock Titan
Incyte Corp (INCY) EVP sells 2,207 shares after option exercise - Stock Titan
Incyte Corp (ICY.HA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte Corp (INCY) 財務データ
収益
当期純利益
現金流量
EPS
0.07%
1.21%
大文字化:
|
ボリューム (24 時間):